Waddell & Reed Financial Inc. Sells 131,464 Shares of Eli Lilly And Co (LLY)

Waddell & Reed Financial Inc. lessened its stake in Eli Lilly And Co (NYSE:LLY) by 11.0% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,062,930 shares of the company’s stock after selling 131,464 shares during the period. Waddell & Reed Financial Inc. owned 0.10% of Eli Lilly And Co worth $90,700,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Greenleaf Trust increased its position in Eli Lilly And Co by 37.7% in the 2nd quarter. Greenleaf Trust now owns 9,815 shares of the company’s stock valued at $838,000 after acquiring an additional 2,686 shares during the period. Van ECK Associates Corp increased its position in Eli Lilly And Co by 10.8% in the 1st quarter. Van ECK Associates Corp now owns 587,502 shares of the company’s stock valued at $45,455,000 after acquiring an additional 57,487 shares during the period. Intrust Bank NA increased its position in Eli Lilly And Co by 6.5% in the 2nd quarter. Intrust Bank NA now owns 9,849 shares of the company’s stock valued at $840,000 after acquiring an additional 597 shares during the period. Homrich & Berg increased its position in Eli Lilly And Co by 8.4% in the 2nd quarter. Homrich & Berg now owns 10,437 shares of the company’s stock valued at $891,000 after acquiring an additional 807 shares during the period. Finally, Private Asset Management Inc. acquired a new position in Eli Lilly And Co in the 2nd quarter valued at about $1,206,000. Hedge funds and other institutional investors own 76.55% of the company’s stock.

Several brokerages recently issued reports on LLY. TheStreet upgraded Eli Lilly And Co from a “c+” rating to a “b” rating in a research report on Friday, June 29th. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $100.00 price objective on the stock in a report on Wednesday, July 18th. Bank of America lifted their price objective on Eli Lilly And Co from $90.00 to $94.00 and gave the company a “neutral” rating in a report on Wednesday, July 25th. Barclays set a $98.00 price objective on Eli Lilly And Co and gave the company a “buy” rating in a report on Tuesday, May 22nd. Finally, BMO Capital Markets lifted their price objective on Eli Lilly And Co from $78.00 to $80.00 and gave the company a “$89.43” rating in a report on Thursday, July 19th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $100.69.

Shares of LLY opened at $105.77 on Friday. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $107.84. The company has a market capitalization of $113.81 billion, a price-to-earnings ratio of 24.71, a price-to-earnings-growth ratio of 1.76 and a beta of 0.28. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.09 and a current ratio of 1.40.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings data on Tuesday, July 24th. The company reported $1.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.30 by $0.20. The company had revenue of $6.36 billion for the quarter, compared to analyst estimates of $6.05 billion. Eli Lilly And Co had a positive return on equity of 39.84% and a negative net margin of 0.60%. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.11 EPS. analysts expect that Eli Lilly And Co will post 5.47 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Monday, September 10th. Stockholders of record on Wednesday, August 15th were paid a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a dividend yield of 2.13%. The ex-dividend date was Tuesday, August 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is 52.57%.

In other news, insider Donald A. Zakrowski sold 600 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $105.57, for a total transaction of $63,342.00. Following the sale, the insider now owns 3,530 shares of the company’s stock, valued at approximately $372,662.10. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 170,000 shares of the business’s stock in a transaction that occurred on Thursday, July 5th. The stock was sold at an average price of $86.62, for a total value of $14,725,400.00. Following the sale, the insider now directly owns 121,880,804 shares in the company, valued at approximately $10,557,315,242.48. The disclosure for this sale can be found here. Insiders have sold a total of 1,685,070 shares of company stock worth $167,108,944 in the last three months. Corporate insiders own 0.11% of the company’s stock.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: What is a Tariff?

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply